318 related articles for article (PubMed ID: 27923629)
21. High expression of dihydropyrimidine dehydrogenase in lung adenocarcinoma is associated with mutations in epidermal growth factor receptor: implications for the treatment of non--small-cell lung cancer using 5-fluorouracil.
Mochinaga K; Tsuchiya T; Nagasaki T; Arai J; Tominaga T; Yamasaki N; Matsumoto K; Miyazaki T; Nanashima A; Hayashi T; Tsukamoto K; Nagayasu T
Clin Lung Cancer; 2014 Mar; 15(2):136-144.e4. PubMed ID: 24405586
[TBL] [Abstract][Full Text] [Related]
22. Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement.
Kim HR; Shim HS; Chung JH; Lee YJ; Hong YK; Rha SY; Kim SH; Ha SJ; Kim SK; Chung KY; Soo R; Kim JH; Cho BC
Cancer; 2012 Feb; 118(3):729-39. PubMed ID: 21720997
[TBL] [Abstract][Full Text] [Related]
23. The prognostic value of serum epidermal growth factor receptor level in patients with non-small cell lung cancer.
Ciledağ A; Kaya A; Yetkin O; Poyraz B; Savaş I; Numanoğlu N; Savaş H
Tuberk Toraks; 2008; 56(4):390-5. PubMed ID: 19123074
[TBL] [Abstract][Full Text] [Related]
24. Total and mutated EGFR quantification in cell-free DNA from non-small cell lung cancer patients detects tumor heterogeneity and presents prognostic value.
Alegre E; Fusco JP; Restituto P; Salas-Benito D; Rodríguez-Ruiz ME; Andueza MP; Pajares MJ; Patiño-García A; Pio R; Lozano MD; Gúrpide A; Lopez-Picazo JM; Gil-Bazo I; Perez-Gracia JL; Gonzalez A
Tumour Biol; 2016 Oct; 37(10):13687-13694. PubMed ID: 27473086
[TBL] [Abstract][Full Text] [Related]
25. Alteration of the E-cadherin/β-catenin complex predicts poor response to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) treatment.
Yoo SB; Kim YJ; Kim H; Jin Y; Sun PL; Jheon S; Lee JS; Chung JH
Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S545-52. PubMed ID: 23579873
[TBL] [Abstract][Full Text] [Related]
26. Utility of serum DNA and pyrosequencing for the detection of EGFR mutations in non-small cell lung cancer.
Akca H; Demiray A; Yaren A; Bir F; Koseler A; Iwakawa R; Bagci G; Yokota J
Cancer Genet; 2013 Mar; 206(3):73-80. PubMed ID: 23491080
[TBL] [Abstract][Full Text] [Related]
27. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.
Sequist LV; Martins RG; Spigel D; Grunberg SM; Spira A; Jänne PA; Joshi VA; McCollum D; Evans TL; Muzikansky A; Kuhlmann GL; Han M; Goldberg JS; Settleman J; Iafrate AJ; Engelman JA; Haber DA; Johnson BE; Lynch TJ
J Clin Oncol; 2008 May; 26(15):2442-9. PubMed ID: 18458038
[TBL] [Abstract][Full Text] [Related]
28. [Relationship between mutations of epidermal growth factor receptor gene and clinicopathologic features of non-small cell lung cancers].
Wang F; Fu S; Tang T; Deng L; Zhang X; Li YZ; Shao JY
Zhonghua Bing Li Xue Za Zhi; 2011 Oct; 40(10):664-6. PubMed ID: 22321543
[TBL] [Abstract][Full Text] [Related]
29. Genetic mutation screen in early non--small-cell lung cancer (NSCLC) specimens.
Bar J; Damianovich M; Hout Siloni G; Dar E; Cohen Y; Perelman M; Ben Nun A; Simansky D; Yellin A; Urban D; Onn A
Clin Lung Cancer; 2014 Mar; 15(2):159-65. PubMed ID: 24370118
[TBL] [Abstract][Full Text] [Related]
30. Classification of Epidermal Growth Factor Receptor Gene Mutation Status Using Serum Proteomic Profiling Predicts Tumor Response in Patients with Stage IIIB or IV Non-Small-Cell Lung Cancer.
Yang L; Tang C; Xu B; Wang W; Li J; Li X; Qin H; Gao H; He K; Song S; Liu X
PLoS One; 2015; 10(6):e0128970. PubMed ID: 26047516
[TBL] [Abstract][Full Text] [Related]
31. Clinical significance of pretreatment plasma biomarkers in advanced non-small cell lung cancer patients.
Wang S; Han X; Hu X; Wang X; Zhao L; Tang L; Feng Y; Wu D; Sun Y; Shi Y
Clin Chim Acta; 2014 Mar; 430():63-70. PubMed ID: 24378285
[TBL] [Abstract][Full Text] [Related]
32. [Detection of epidermal growth factor receptor mutations in non-small cell lung cancer by real-time PCR using TaqMan-MGB probes].
Zhou CC; Zhou SW; Pan H; Su B; Gao ZQ
Zhonghua Zhong Liu Za Zhi; 2007 Feb; 29(2):119-23. PubMed ID: 17645848
[TBL] [Abstract][Full Text] [Related]
33. EGFR mutations detected on cytology samples by a centralized laboratory reliably predict response to gefitinib in non-small cell lung carcinoma patients.
Malapelle U; Bellevicine C; De Luca C; Salatiello M; De Stefano A; Rocco D; de Rosa N; Vitiello F; Russo S; Pepe F; Iaccarino A; Micheli P; Illiano A; Carlomagno C; Piantedosi FV; Troncone G
Cancer Cytopathol; 2013 Oct; 121(10):552-60. PubMed ID: 23780873
[TBL] [Abstract][Full Text] [Related]
34. Abnormalities of epidermal growth factor receptor in lung squamous-cell carcinomas, adenosquamous carcinomas, and large-cell carcinomas: tyrosine kinase domain mutations are not rare in tumors with an adenocarcinoma component.
Ohtsuka K; Ohnishi H; Fujiwara M; Kishino T; Matsushima S; Furuyashiki G; Takei H; Koshiishi Y; Goya T; Watanabe T
Cancer; 2007 Feb; 109(4):741-50. PubMed ID: 17238183
[TBL] [Abstract][Full Text] [Related]
35. Association between downexpression of MiR-203 and poor prognosis in non-small cell lung cancer patients.
Tang R; Zhong T; Dang Y; Zhang X; Li P; Chen G
Clin Transl Oncol; 2016 Apr; 18(4):360-8. PubMed ID: 26307752
[TBL] [Abstract][Full Text] [Related]
36. Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer.
Yang X; Zhuo M; Ye X; Bai H; Wang Z; Sun Y; Zhao J; An T; Duan J; Wu M; Wang J
Oncotarget; 2016 Apr; 7(15):20810-24. PubMed ID: 26989078
[TBL] [Abstract][Full Text] [Related]
37. Clinical outcome with platinum-based chemotherapy in patients with advanced nonsquamous EGFR wild-type non-small-cell lung cancer segregated according to KRAS mutation status.
Metro G; Chiari R; Bennati C; Cenci M; Ricciuti B; Puma F; Flacco A; Rebonato A; Giannarelli D; Ludovini V; Bellezza G; Ferolla P; Minotti V; Crinò L
Clin Lung Cancer; 2014 Jan; 15(1):86-92. PubMed ID: 24139827
[TBL] [Abstract][Full Text] [Related]
38. [Epidermal growth factor receptor gene mutations and clinicopathologic correlation in 309 patients with non-small cell lung cancer].
Feng Q; Li XH; Chen Z; He JS; Wang CX; Zhou LX; Xue WC
Zhonghua Bing Li Xue Za Zhi; 2011 Oct; 40(10):660-3. PubMed ID: 22321542
[TBL] [Abstract][Full Text] [Related]
39. Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations.
Yeo CD; Park KH; Park CK; Lee SH; Kim SJ; Yoon HK; Lee YS; Lee EJ; Lee KY; Kim TJ
Lung Cancer; 2015 Mar; 87(3):311-7. PubMed ID: 25617986
[TBL] [Abstract][Full Text] [Related]
40. Association of exon 19 and 21 EGFR mutation patterns with treatment outcome after first-line tyrosine kinase inhibitor in metastatic non-small-cell lung cancer.
Lee VH; Tin VP; Choy TS; Lam KO; Choi CW; Chung LP; Tsang JW; Ho PP; Leung DK; Ma ES; Liu J; Shek TW; Kwong DL; Leung TW; Wong MP
J Thorac Oncol; 2013 Sep; 8(9):1148-55. PubMed ID: 23945384
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]